Table 2

Disease activity (including DAS28 variables), EULAR response rates and HAQ score at time points (observed data)

AbataceptTocilizumab
Week 0 (baseline)Week 6Week 12Week 24Week 36Week 48Week 0 (baseline)Week 6Week 12Week 24Week 36Week 48
Patients receiving drug (n)150138118967660178154124955931
Patients with response data (n)1047679574738976965513719
Disease activity level (%)
 Remission08919212621720393558
 Low181421621391516160
 Moderate424557446242365954394132
 High5739201611115914116811
EULAR response rates (%)
 Good11224023452934455458
 Moderate28413051323949433026
 None62383026243217121616
DAS28 variables, median (IQR)
 DAS285.3 (4.7–6.1)4.8* (3.675–5.7)3.9* (3.25–4.95)3.4* (2.7–4.9)3.9* (3.05–4.6)3.3* (2.5–4.3)5.4 (4.7–6.2)3.9* (3.1–4.8)3.5* (2.9–4.3)2.9* (2.25–3.95)3.1* (2.2–4.3)2.5* (1.9–4.5)
 SJC (0–28)5 (2–9)3 (1–6)2* (0.5–4.5)2* (0–4.5)1* (0–4)1* (0–2.25)5 (3–10)3* (0.75–5)2* (0–3)2* (0–3)1* (0–2.5)1* (0–1)
 TJC (0–28)12 (6.75–17)7* (4–13.5)4* (1–10)2.5* (0–8)3.5* (0–6)1* (0–5.25)11 (5–18)5* (2–12)4*(1–10)2*(1–6.25)2* (0–7.5)1 (0–10)
 CRP (mg/l)15 (4–40)11 (5–27.75)10 (4–27)9* (4–20)10 (5–26)8* (3.5–16.5)18 (7–43)3* (1–6)4* (1–7)2.5* (1–5)4* (1–6.75)1* (1–5)
 Patient global score (0–100)66 (50.75–80.25)58.5 (33.75–80)45.5* (30–63.75)37* (23.5–55.5)40* (24–61)28* (16–56)71 (55–82)63* (28–75)47* (24.5–67)35* (15–57)29* (16.5–58.75)18* (14–58)
HAQ score1.5 (1–2)1.38 (0.88–1.88)1.13* (0.75–1.75)1* (0.38–1.75)1.06* (0.63–1.63)1* (0.38–1.5)1.5 (1–2)1.25* (0.75–1.88)1.13* (0.63–1.5)1* (0.5–1.25)0.75* (0.63–1.25)1* (0.5–1.38)
  • * Significantly reduced (p≤0.001), compared with baseline.

  • Significantly reduced (p≤0.01), compared with baseline.

  • CRP, C reactive protein; DAS28, 28-joint count Disease Activity Score; EULAR response, European League Against Rheumatism response; HAQ score, Health Assessment Questionnaire score; SJC, swollen joint count; TJC, tender joint count.